Cargando…

Pre-activation of autophagy impacts response to olaparib in prostate cancer cells

Poly (ADP-ribose) polymerase 1 (PARP1) plays an essential role in DNA repair and is targeted by anticancer therapies using PARP inhibitors (PARPi) such as olaparib. PARPi treatment in prostate cancer (PC) is currently used as a monotherapy or in combination with standard therapies (hormonotherapy) i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cahuzac, Maxime, Langlois, Patricia, Péant, Benjamin, Fleury, Hubert, Mes-Masson, Anne-Marie, Saad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940895/ https://www.ncbi.nlm.nih.gov/pubmed/35318456 http://dx.doi.org/10.1038/s42003-022-03210-5

Ejemplares similares

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
por: Cahuzac, Maxime, et al.
Publicado: (2022)

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer
por: Gilbert, Sophie, et al.
Publicado: (2022)

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022)

Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality
por: Clairefond, Sylvie, et al.
Publicado: (2021)

PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence
por: Clairefond, Sylvie, et al.
Publicado: (2020)

Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2020)

Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems
por: Patra, Bishnubrata, et al.
Publicado: (2020)

Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2021)

NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer
por: Boudhraa, Zied, et al.
Publicado: (2021)

Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
por: Amuzu, Setor, et al.
Publicado: (2021)

Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay
por: Labouba, Ingrid, et al.
Publicado: (2015)

IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
por: Péant, Benjamin, et al.
Publicado: (2016)

Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
por: Gannon, Philippe O., et al.
Publicado: (2010)

A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
por: Communal, Laudine, et al.
Publicado: (2021)

High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality
por: Dariane, Charles, et al.
Publicado: (2022)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

The RelB alternative NF-kappaB subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo
por: Labouba, Ingrid, et al.
Publicado: (2014)

Ebp1 expression in benign and malignant prostate
por: Gannon, Philippe O, et al.
Publicado: (2008)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
por: De Felice, Francesca, et al.
Publicado: (2017)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

Influence of pH on the Cytotoxic Activity of Inositol Hexakisphosphate (IP6) in Prostate Cancer
por: Betton, Blandine, et al.
Publicado: (2011)

Microdissected Tissue vs. Tissue Slices—A Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip
por: Dorrigiv, Dina, et al.
Publicado: (2021)

Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models
por: Brodeur, Melica Nourmoussavi, et al.
Publicado: (2021)

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
por: Wang, Zhenwei, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease
por: Fleury, Hubert, et al.
Publicado: (2015)

High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients
por: Geoffroy, Karen, et al.
Publicado: (2022)

Describing perspectives of health care professionals on active surveillance for the management of prostate cancer
por: Pang, Kittie, et al.
Publicado: (2018)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib
por: Gong, Lifeng, et al.
Publicado: (2022)

Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer
por: Asare-Werehene, Meshach, et al.
Publicado: (2019)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

Comparing Perspectives of Canadian Men Diagnosed With Prostate Cancer and Health Care Professionals About Active Surveillance
por: Fitch, Margaret, et al.
Publicado: (2020)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance
por: Horak, Peter, et al.
Publicado: (2019)

Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients
por: Zhang, Dong, et al.
Publicado: (2022)

Canadian Men’s perspectives about active surveillance in prostate cancer: need for guidance and resources
por: Fitch, Margaret, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4aqr1mi216qehb5cd911ani7ci